Antisense therapeutics in oncology: Points to consider in their clinical evaluation

Sridhar Mani, Yun Gu, Scott Wadler, Howard Fingert

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalAntisense and Nucleic Acid Drug Development
Volume9
Issue number6
StatePublished - 1999

Fingerprint

Oncology
Cytostatic Agents
Drug Delivery Systems
Cell growth
Apoptosis
Toxicity
Tumors
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

Antisense therapeutics in oncology : Points to consider in their clinical evaluation. / Mani, Sridhar; Gu, Yun; Wadler, Scott; Fingert, Howard.

In: Antisense and Nucleic Acid Drug Development, Vol. 9, No. 6, 1999, p. 543-547.

Research output: Contribution to journalArticle

@article{bb81664b2e754a0fb0d873a2a90a010a,
title = "Antisense therapeutics in oncology: Points to consider in their clinical evaluation",
abstract = "Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.",
author = "Sridhar Mani and Yun Gu and Scott Wadler and Howard Fingert",
year = "1999",
language = "English (US)",
volume = "9",
pages = "543--547",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Antisense therapeutics in oncology

T2 - Points to consider in their clinical evaluation

AU - Mani, Sridhar

AU - Gu, Yun

AU - Wadler, Scott

AU - Fingert, Howard

PY - 1999

Y1 - 1999

N2 - Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.

AB - Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.

UR - http://www.scopus.com/inward/record.url?scp=0033427291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033427291&partnerID=8YFLogxK

M3 - Article

C2 - 10645781

AN - SCOPUS:0033427291

VL - 9

SP - 543

EP - 547

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 6

ER -